Breast Cancer Update Home - Oncology Leader Commentary

Home: Oncology Leader Commentary: Andrew D. Seidman, MD

Click on the topic below for comments by Dr Andrew D. Seidman to comment on. You will also find links to related articles and clinical trials.

HER-2 and selection of adjuvant therapy
Adjuvant chemotherapy for node-positive patients
Adjuvant chemotherapy plus tamoxifen in ER+ patients
Aromatase inhibitors in women with increased risk of thromboembolic complications
Tamoxifen rechallenge in the metastatic setting
Trials of adjuvant Arimidex
Aromatase inhibitors in women who cannot receive adjuvant tamoxifen
Choice of aromatase inhibitors
Chemotherapy followed by endocrine therapy for metastatic disease
Herceptin for metastatic disease
Herceptin as a single agent for metastatic disease
HER-2 assays
Trials correlating activity of Herceptin with HER 2 assay
Effect of Herceptin in "HER2-negative" patients

Home

Patrick I. Borgen, MD

Aman Buzdar, MD

Nancy E. Davidson, MD

J. Michael Dixon, MD

Armando Giuliano, MD

I. Craig Henderson, MD

David Krag, MD

Gershon Locker, MD

Charles Loprinzi, MD

Richard Margolese, MD

Monica Morrow, MD

C Kent Osborne, MD

Sir Richard Peto, FRS

Kathy I. Pritchard, MD

John F. Robertson, MD,FRCS

Andrew D. Seidman, MD

George W. Sledge, MD

Home · Contact us

Terms of use and general disclaimer